A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

While the year started out as cautiously optimistic, stemming from the peak of biotech initial public offering (IPO) activity ...

The EU has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, more than two years after it was filed.

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at up-to-date safety data on Leqembi (lecanemab) at its next meeting in ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

President Donald Trump arrived Friday in Texas for a firsthand look at the devastation from the state's catastrophic flooding ...

Either Amanda Anisimova or Iga Swiatek will leave the All England Club's grass courts as Wimbledon's eighth consecutive first ...

A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...